Be aware of the fair value of a drug is a conviction that has inspired Pharma Value's actions, right from the choice of name, as well as being, in our opinion, the key to a successful strategy.
We have published on our website the Pharma Value Code of Ethics with the intention of sharing corporate values and rules of conduct and of fostering a conscious adherence to the value orientation by employees and collaborators, as well as a clear positioning within our industry.
Attention to the context and needs of stakeholders but also to their ability to contribute to and influence the building a healthy and sustainable environmentfor us, it means acting with a shared value system as a reference that guides us consistently in our actions and relationships.
The Code represents a key document in which the values, principles guiding the actions, commitments and set of rights and duties of all those who, in whatever capacity, enter into relations with our Company are identified.
We are convinced that promoting the ethical principles in which we believe generates added value and contributes to increasing the well-being of employees and collaborators, the satisfaction of client companies and, more generally, benefits all stakeholders.
To ensure respect for gender identity, the Code was drafted with a fair and inclusive languageaccording to the European Parliament's guidelines on gender neutrality in language .
Pharma Value undertakes to observe, respect and share the principles contained in the Code of Ethics, which have as their prerequisite the compliance with all legal regulations and the adoption of ethically correct conductboth internally and externally, and requires that employees and collaborators do the same, each with their own behaviour and actions.
We work hard every day to create and manage respectful, fair and transparent human relations so that the trust placed in us is strengthened, reciprocated and multiplied.

Draft document on the evaluation criteria for the attribution of therapeutic innovativeness
On March 12, 2025, AIFA published the draft document on the “Evaluation Criteria for the Attribution of Therapeutic Innovation and the Management of Antiinfective Agents for Multidrug-Resistant